Summary
0M26 Chart
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago.
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields with cumulative, perpetual dividends. Since XOMA's diversified portfolio features high-potential, recently FDA-approved assets like Ojemda and Miplyffa, I also think the yields should be relatively secure.
What Makes XOMA Royalty (XOMA) a New Buy Stock
XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
XOMA Corporation Dividends
XOMA Corporation Earnings
| 12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | 0.06 EPS |
| 6 Mar 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | 0.06 EPS |
| 6 Mar 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
XOMA Corporation (0M26) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has XOMA Corporation ever had a stock split?
XOMA Corporation Profile
| Biotechnology Industry | Healthcare Sector | Owen P. Hughes Jr. CEO | LSE Exchange | US98419J2069 ISIN |
| US Country | 13 Employees | - Last Dividend | 18 Aug 2010 Last Split | 16 Dec 2020 IPO Date |
Overview
XOMA Corporation is a unique entity in the biotech space, categorizing itself as a biotech royalty aggregator. Based in Emeryville, California, and operational since 1981, the company has carved a niche for itself by focusing on the aggregation of economic rights related to milestone and royalty payments. These payments are expected from partnered therapeutic candidates, which are either in the commercial stage or the pre-commercial development stages across the United States and the Asia Pacific region. By centering its operations on acquiring these revenue streams from both commercial and late-stage clinical assets, XOMA leverages the potential financial returns without directly involving itself in the development, manufacturing, or marketing of these therapeutic solutions.
Products and Services
- Economic Rights Acquisition:
XOMA’s core business model involves acquiring economic rights to future potential milestone and royalty payments across a broad spectrum of therapeutic candidates. This innovative approach allows XOMA to benefit from the success of a wide range of therapies without bearing the significant costs and risks associated with their development.
- Partnered Commercial and Pre-Commercial Therapeutic Candidates:
The company’s portfolio is diverse, encompassing a variety of therapeutic candidates that are either in the commercial stage or moving towards it. These candidates are licensed to partners who manage their development, allowing XOMA to collect milestone payments and royalties upon their commercial success.
- Focus on Early to Mid-Stage Clinical Assets:
In its selective investment strategy, XOMA emphasizes the licensing of early to mid-stage clinical assets, especially those in Phase 1 and 2. The company seeks assets with high commercial sales potential, enabling it to secure a financial stake in their success at an earlier phase of development.
- Acquisition of Milestone and Royalty Revenue Streams:
Further solidifying its business model, XOMA also focuses on acquiring existing milestone and royalty revenue streams from late-stage clinical or already commercialized assets. This strategy provides a more immediate financial return while maintaining a diversified portfolio.
Contact Information
